Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291965 · ClinicalTrials.gov registry record
Blood Samples to Identify Biomarkers of Busulfan
A clinical trial, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- 139
- Enrollment target
NCT02291965: Clinical Trial study, sponsored by Fred Hutchinson Cancer Center.
NCT02291965 is a clinical trial that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02291965 was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- 139 participants
- Enrollment target
Study Summary
Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance. Specific Aim 2: To characterize IV BU metabolism by metabolomics. Specific Aim 3: To identify covariates influencing IV BU pharmacokinetics.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2014-11 |
| Est. Completion | 2024-10-07 |
Why NCT02291965 stopped before completion
NCT02291965 is an observational study that tracks outcomes without assigning an intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02291965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02291965 about?
NCT02291965 is a clinical study titled "Blood Samples to Identify Biomarkers of Busulfan". Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance. Specific Aim 2: To characterize IV BU metabolism by metabolomics. Specific Aim 3: To identify covariates influencing IV BU pharmacokinetics.
What is the current status of trial NCT02291965?
This trial is currently terminated. The enrollment target is 139 participants. The study started on 2014-11. Estimated completion is 2024-10-07.
Who is sponsoring clinical trial NCT02291965?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia